“The highly compelling results of our Phase 2b NAVIGATE trial for CD388 and subsequent financing puts us in a position of strength to execute on our Phase 3 plan to examine the potential of CD388, a non-vaccine solution, to provide single-dose per season, universal protection against influenza in individuals at greatest risk from influenza,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Our planned Phase 3 development program focuses initially on individuals with compromised immune systems or those at a heightened risk of severe illness due to underlying health conditions. We have submitted an End-of-Phase 2 meeting request to the FDA to discuss our planned Phase 3 study design and start timing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $115 from $75 at RBC Capital
- Cidara Therapeutics price target raised to $69 from $68 at Guggenheim
- Cidara Therapeutics announces inclusion in Russell 2000, 3000 Indexes
- Cidara Therapeutics Announces $350 Million Stock Offering
- Cidara Therapeutics 7.95M share Secondary priced at $44.00